3.4500 +0.02 (0.44%)
After hours: 7:33PM EDT
|Bid||3.3500 x 3000|
|Ask||3.4400 x 1800|
|Day's range||3.1000 - 3.5000|
|52-week range||2.4500 - 7.9400|
|Beta (5Y monthly)||1.82|
|PE ratio (TTM)||N/A|
|Earnings date||13 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.25|
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 3.23% and 6.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced financial results for the first quarter 2021 and recent highlights.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in following upcoming virtual events: